Learn more› Live updates By The Deals Team The Deals team hunts for and highlights only the best discounts on picks made by ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...